Literature DB >> 23082731

Should dendritic cell-based tumor vaccination be incorporated into standard therapy for newly diagnosed glioblastoma patients?

Stefaan Van Gool, Steven De Vleeschouwer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23082731     DOI： 10.1586/ern.12.107

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN： 1473-7175            Impact factor:   4.618


× No keyword cloud information.
  3 in total

Review 1.  Brain Tumor Immunotherapy: What have We Learned so Far?

Authors:  Stefaan Willy Van Gool
Journal:  Front Oncol       Date:  2015-06-17       Impact factor: 6.244

2.  Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?

Authors:  Matthias van Woensel; Nathalie Wauthoz; Rémi Rosière; Karim Amighi; Véronique Mathieu; Florence Lefranc; Stefaan W van Gool; Steven de Vleeschouwer
Journal:  Cancers (Basel)       Date:  2013-08-14       Impact factor: 6.639

3.  Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis.

Authors:  Jun-Xia Cao; Xiao-Yan Zhang; Jin-Long Liu; Duo Li; Jun-Li Li; Yi-Shan Liu; Min Wang; Bei-Lei Xu; Hai-Bo Wang; Zheng-Xu Wang
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.